As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediate-risk prostate cancer treated with extreme hypofractionated radiotherapy (RT) and simultaneous boost to the intraprostatic lesion. The aim of the study is to identify clinically meaningful information through the analysis of validated questionnaires testing gastrointestinal (GI) and genitourinary (GU) RT-related toxicity and their impact on quality of life (QoL). At the end of RT treatment, clinical assessment and prostate-specific antigen (PSA) measurements were performed every 3 months for at least 2 years and GI and GU toxicities were evaluated contextually. QoL of enrolled patients was assessed by International Prostate Symptoms score (IPSS), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Core 30 (EORTC QLQ-C30), EORTC QLQ prostate specific (QLQ-PR25), and sexual activity by International Index of Erectile Function (IIEF-5). Patients’ score changes were calculated at the end of RT, at one month after RT and at 12 and 24 months. Sixty-five prospectively enrolled patients were analyzed. Extensive analysis of different QoL assessments showed that patients’ tolerance was satisfactory across all the considered time points, with no statistically significant change of QoL from baseline compared to that before RT. Overall survival and biochemical progression-free survival at 2-years were of 98% and 97%, respectively. Despite the toxicity of extreme hypofractionation was low and tumor control was encouraging, a longer follow-up is necessary to confirm our findings. The increasing dose to the dominant intraprostatic lesion does not worsen the RT toxicity and consequently does not affect patients’ QoL, thus questioning the possibility of an even more escalated treatment.

Phase II prospective trial “Give Me Five” short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion : the impact of toxicity on quality of life (AIRC IG-13218) / G. Marvaso, S.G. Gugliandolo, F. Bellerba, S. Gandini, G. Corrao, S. Volpe, D.P. Rojas, G. Riva, D. Zerini, M. Pepa, C.I. Fodor, E. La Rocca, P. Pricolo, S. Alessi, G. Petralia, F.A. Mistretta, R. Cambria, F. Cattani, O. De Cobelli, R. Orecchia, B.A. Jereczek-Fossa. - In: MEDICAL ONCOLOGY. - ISSN 1357-0560. - 37:8(2020), pp. 74.1-74.11. [10.1007/s12032-020-01397-3]

Phase II prospective trial “Give Me Five” short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion : the impact of toxicity on quality of life (AIRC IG-13218)

G. Marvaso
;
F. Bellerba;S. Volpe;D.P. Rojas;D. Zerini;P. Pricolo;G. Petralia;F.A. Mistretta;O. De Cobelli;R. Orecchia;B.A. Jereczek-Fossa
2020

Abstract

As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediate-risk prostate cancer treated with extreme hypofractionated radiotherapy (RT) and simultaneous boost to the intraprostatic lesion. The aim of the study is to identify clinically meaningful information through the analysis of validated questionnaires testing gastrointestinal (GI) and genitourinary (GU) RT-related toxicity and their impact on quality of life (QoL). At the end of RT treatment, clinical assessment and prostate-specific antigen (PSA) measurements were performed every 3 months for at least 2 years and GI and GU toxicities were evaluated contextually. QoL of enrolled patients was assessed by International Prostate Symptoms score (IPSS), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Core 30 (EORTC QLQ-C30), EORTC QLQ prostate specific (QLQ-PR25), and sexual activity by International Index of Erectile Function (IIEF-5). Patients’ score changes were calculated at the end of RT, at one month after RT and at 12 and 24 months. Sixty-five prospectively enrolled patients were analyzed. Extensive analysis of different QoL assessments showed that patients’ tolerance was satisfactory across all the considered time points, with no statistically significant change of QoL from baseline compared to that before RT. Overall survival and biochemical progression-free survival at 2-years were of 98% and 97%, respectively. Despite the toxicity of extreme hypofractionation was low and tumor control was encouraging, a longer follow-up is necessary to confirm our findings. The increasing dose to the dominant intraprostatic lesion does not worsen the RT toxicity and consequently does not affect patients’ QoL, thus questioning the possibility of an even more escalated treatment.
Clinical trial; Dominant intraprostatic lesion; Extreme hypofractionation; Prostate cancer; Quality of life
Settore MED/24 - Urologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
Phase II.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 857.34 kB
Formato Adobe PDF
857.34 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/821978
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact